MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

DiscussionResults will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials.Trial registrationAndalusia:NCT01745783, registered on Dec 10, 2012.Badalona:NCT02035514 EudraCT, 2010 –024081–21. Registered on 2012.Canada: ClinicalTrials.gov,NCT02239393. Registered on September 12, 2014.Copenhagen: EudraCT,2012 –000518-13. Registered on June 21, 2012.Italy: EudraCT, 2011 –001295-19, and ClinicalTrials.gov,NCT01854957. Retrospectively registered on May 16, 2013.London: Eudra CT 2012 –002357-35, and ClinicalTrials.gov,NCT01606215. Registered on May 25, 2012.Salzburg: EudraCT,2015 –000137-78. Registered on September 15, 2015.Stockholm: ClinicalTrials.gov,NCT01730547. Registered on November 21, 2012.Toulouse: ClinicalTrials.gov,NCT02403947. Registered on March 31, 2015.
Source: Trials - Category: Research Source Type: clinical trials